#UK #Piramal Pharma #Morpeth Facility #Morpeth #Korsch X3

Celebrating 20 Years of Pharmaceutical Excellence at Piramal Pharma Solutions

Piramal Pharma Solutions is reaching a significant milestone as it commemorates two decades of excellence at its Morpeth facility in the UK. On this momentous occasion, the company proudly announces the installation of a state-of-the-art Korsch X3 high containment tablet press. This acquisition not only marks the progress of the Morpeth site but also emphasizes Piramal's ongoing commitment to providing innovative solutions in the pharmaceutical manufacturing landscape.

The Korsch X3: A Technological Leap Forward

Designed to meet the specific needs of modern pharma manufacturing, the Korsch X3 tablet press represents a leap forward in technology. With full Band 5 containment, this press ensures the safe and efficient production of highly potent drug products on both clinical and commercial scales. The addition of the Korsch X3 enhances the facility's ability to meet increasing demands for complex therapies, enabling quicker delivery of life-saving treatments to patients.

The facility recently commissioned a smaller model, the Korsch XM12 Single Layer/Bilayer press, to solidify its commitment to innovative technology in drug manufacturing. However, with the rising demand in late-phase and commercial markets, the team recognized the necessity for a more advanced machine capable of handling varying tablet sizes. The Korsch X3 was chosen after a long-standing relationship with Korsch, a respected name in the industry.

Unique Features and Benefits

What sets the Korsch X3 apart from traditional tablet presses is its custom configuration tailored for handling highly potent active pharmaceutical ingredients (HPAPIs). With dual customized turrets, the press can manufacture tablets of 25mm, broadening the range of formulations it can produce. Additionally, the Korsch X3 boasts greater operational efficiency and increased tablet strength.

The machine features a contained infeed mechanism, reducing risks associated with open scooping into the feed hopper. Using a split butterfly valve for transitions and sanitary fittings, along with a contained finished product chute, allows core tablets to proceed directly to coating operations seamlessly. This sophisticated design contributes to both safety and efficiency in the production process.

Moreover, the X3 incorporates enhanced containment measures, making it suitable for working with high-toxicity drugs. With front and dual-side glove ports, along with a misting system to minimize residual dust, the equipment is designed to protect staff from airborne contaminants during manufacturing and changeovers.

Training and Implementation

To ensure the safe and effective use of the new press, the site team has undergone thorough training, including onsite practical sessions with Korsch. This preparation is integral for building the team's confidence in handling the advanced technology and will play a crucial role in upholding workplace safety standards.

Peter DeYoung, CEO of Piramal Global Pharma, shared, "By expanding Morpeth's capacity to manufacture tablets with Band 5 HPAPIs, the Korsch X3 enhances our ability to serve patients in therapeutic areas where high potency materials are essential, such as hormonals. Celebrating the site’s 20-year anniversary with this acquisition reinforces our legacy of improving and extending patients' lives."

A Commitment to the Future

As Morpeth marks its 20 years of excellence in pharmaceutical manufacturing, the introduction of the Korsch X3 serves as a strong testament to its dedication to innovation and patient-centered care. This milestone is not just a reflection of the past two decades but is also a commitment to a future where more patients can benefit from Piramal’s advanced capabilities.

Piramal Pharma Solutions continues to invest in technology that ultimately supports its vision of delivering high-quality materials, ensuring the manufacturing of safe and effective therapies for people worldwide. Resting on the successful foundation built over the past twenty years, the future looks promising for Morpeth and Piramal Pharma Solutions as they aim to further enhance their position in the global pharmaceutical industry.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) committed to offering comprehensive drug development and manufacturing solutions at every stage of the drug life cycle. With facilities across North America, Europe, and Asia, PPS provides an extensive range of services, ensuring reliable and efficient support to its clients throughout the pharmaceutical landscape.

For further information, contact Piramal Pharma Solutions online or follow them on their social media channels.